[go: up one dir, main page]

CA950833A - Composition for the treatment of hypertrophied oral tissue - Google Patents

Composition for the treatment of hypertrophied oral tissue

Info

Publication number
CA950833A
CA950833A CA104,265,A CA104265A CA950833A CA 950833 A CA950833 A CA 950833A CA 104265 A CA104265 A CA 104265A CA 950833 A CA950833 A CA 950833A
Authority
CA
Canada
Prior art keywords
hypertrophied
treatment
composition
oral tissue
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA104,265,A
Other versions
CA104265S (en
Inventor
Carl M. Kosti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA104,265,A priority Critical patent/CA950833A/en
Application granted granted Critical
Publication of CA950833A publication Critical patent/CA950833A/en
Expired legal-status Critical Current

Links

CA104,265,A 1971-02-02 1971-02-02 Composition for the treatment of hypertrophied oral tissue Expired CA950833A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA104,265,A CA950833A (en) 1971-02-02 1971-02-02 Composition for the treatment of hypertrophied oral tissue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA104,265,A CA950833A (en) 1971-02-02 1971-02-02 Composition for the treatment of hypertrophied oral tissue

Publications (1)

Publication Number Publication Date
CA950833A true CA950833A (en) 1974-07-09

Family

ID=4088649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA104,265,A Expired CA950833A (en) 1971-02-02 1971-02-02 Composition for the treatment of hypertrophied oral tissue

Country Status (1)

Country Link
CA (1) CA950833A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US9463199B2 (en) 2004-03-25 2016-10-11 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US9616134B2 (en) 2006-11-07 2017-04-11 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10071162B2 (en) 2013-07-19 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10117869B2 (en) 2004-03-25 2018-11-06 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364616A (en) * 1992-04-15 1994-11-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US10537588B2 (en) 2004-03-25 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US9463199B2 (en) 2004-03-25 2016-10-11 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US9889148B2 (en) 2004-03-25 2018-02-13 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US11413285B2 (en) 2004-03-25 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US10117869B2 (en) 2004-03-25 2018-11-06 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US9616134B2 (en) 2006-11-07 2017-04-11 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10639305B2 (en) 2006-11-07 2020-05-05 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US11185590B2 (en) 2013-07-19 2021-11-30 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10071162B2 (en) 2013-07-19 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US12011441B2 (en) 2016-04-06 2024-06-18 Boehringer Ingelheim Vetmedica Gmbh Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Similar Documents

Publication Publication Date Title
AU5678773A (en) Treatment of teeth
AU3903472A (en) Surgical sponge
CA987598A (en) Cleansing of dentures
CA950833A (en) Composition for the treatment of hypertrophied oral tissue
AU470321B2 (en) Treatment of teeth
CA963204A (en) Treatment of pigments
AU451333B2 (en) Treatment of arabinogalactan
PH10039A (en) Compositions for the treatment of human hair
AU472168B2 (en) Treatment of titanium
CA1008370A (en) Product for the treatment of keratinous tissues
AU466300B2 (en) Composition for the treatment of hyperlipoproteinaemia
CA986022A (en) Dental treatment compositions including n-monochloroglycine
AU458749B2 (en) Process for the treatment and care of dentures
CA936653A (en) Treatment of titanium dioxide
ZA724724B (en) Pharmaceutical compositions for treatment of bronchial diseases
CA999238A (en) Oral or dental preparation
AU475165B2 (en) Treatment of respiration conditions using hydroxycyclohexylamino compounds
AU463836B2 (en) Composition for treatment of asthma
ZA75607B (en) Pharmaceutical composition for the treatment of cancer
CA837050A (en) Method of and composition for the treatment of human carcinoma and hypercholestrolemia
CA1026672A (en) Pharmaceutical composition for the treatment of cancer
CA878459A (en) Medicine for the treatment of hemeralopia
AU439164B2 (en) Oral compositions for treatment of hypercholes teremia
AU491991B2 (en) Pharmaceutical composition for the treatment of coronaric ailiments
AU459945B2 (en) Treatment of keratinous substrates